Genentech Inc. and Germany’s BioNTech AG believe that together they can leverage the US-based Roche division’s portfolio of approved and investigational cancer immunotherapies and the privately-held biotech’s proprietary mRNA cancer vaccine technology platform to develop bespoke cancer vaccines for individual patients.
Most approaches to cancer vaccines have been unsuccessful due to difficulties identifying the correct cancer targets, or antigens, to vaccinate against. But the duo says that with advanced sequencing and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?